AKTS vs GLUE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
AKTS · Aktis Oncology$15.82 ▲ 6.53%
GLUE · Monte Rosa Therapeutics$10.57 ▲ 3.12%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- AKTS -29.4%
- GLUE -56.5%
Head to head
| Metric | AKTS | GLUE |
|---|---|---|
| Price | $15.82 | $10.57 |
| Change today | ▲ 6.53% | ▲ 3.12% |
| Market cap | $879.90M | $903.21M |
| Return, 3 months | -34.4% | -33.2% |
| Return, year to date | – | -32.6% |
| Return, 1 year | – | -14.1% |
| P/E (TTM) | – | – |
| P/B | 1.8 | 1.8 |
| P/E percentile vs own 5y | 97th | 12th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +111.4% | -61.3% |
| Net profit growth (YoY) | -33.6% | -253.0% |
| Gross margin | – | – |
| Operating margin | -866.6% | -633.0% |
| Net margin | -727.0% | -560.9% |
| Return on equity | -15.1% | -42.7% |
| Analyst target vs. price | +126.3% | +157.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 42 | 45 |
| 30-day volatility | 58.7% | 58.0% |
| Max drawdown, 1 year | -54.7% | -61.5% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GLUE is the largest of the group by market value.
- AKTS is growing revenue fastest.
- GLUE keeps the most profit per dollar of sales.
- GLUE has been the calmest stock over the last 30 days.